These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 23628133)

  • 1. Statistical analysis of dose-volume profiles and its implication for radiation therapy planning in prostate carcinoma.
    Vanasek J; Odrazka K; Dolezel M; Kolarova I; Jarkovsky J; Pavlik T; Hlavka A; Dusek L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):769-76. PubMed ID: 23628133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
    Aillères N; Azria D; Thézenas S; Barbier N; Fenoglietto P; Delard R; Hay MH; Dubois JB
    Cancer Radiother; 2004 Apr; 8(2):59-69. PubMed ID: 15063872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct effects of rectum delineation methods in 3D-conformal vs. IMRT treatment planning of prostate cancer.
    Guckenberger M; Meyer J; Baier K; Vordermark D; Flentje M
    Radiat Oncol; 2006 Sep; 1():34. PubMed ID: 16956403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anal wall sparing effect of an endorectal balloon in 3D conformal and intensity-modulated prostate radiotherapy.
    Smeenk RJ; van Lin EN; van Kollenburg P; Kunze-Busch M; Kaanders JH
    Radiother Oncol; 2009 Oct; 93(1):131-6. PubMed ID: 19523704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk.
    Fenoglietto P; Laliberte B; Allaw A; Ailleres N; Idri K; Hay MH; Moscardo CL; Gourgou S; Dubois JB; Azria D
    Radiother Oncol; 2008 Jul; 88(1):77-87. PubMed ID: 18215434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
    Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.
    Michalski JM; Yan Y; Watkins-Bruner D; Bosch WR; Winter K; Galvin JM; Bahary JP; Morton GC; Parliament MB; Sandler HM
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):932-8. PubMed ID: 24113055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
    Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of benchmark dose-volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer.
    Luo C; Yang CC; Narayan S; Stern RL; Perks J; Goldberg Z; Ryu J; Purdy JA; Vijayakumar S
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1253-62. PubMed ID: 17145540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
    Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.